Subscribe To

Price Alert Latest News Economic Calendar News

MRK / Merck's combination therapy in lung cancer fails a Phase 2 clinical trial

Merck & Co. Inc. MRK, -0.27% said late Thursday that its combination therapy of vibostolimab and Keytruda did not outperform chemotherapy in a Phase 2 clinical trial of patients with metastatic non-small cell lung cancer. The company also said the study did not meet the primary endpoint of progression-free survival, and it plans to continue to evaluate the combo therapy with docetaxel against docetaxel. Read More

Demo Live Account See Partner Details

Content Topics

Merck

Combination

Therapy

Lung

Cancer

Fails

Phase

Clinical

Merck s

Stock

MRK

Posted: Mar 17 2023, 08:08

Author Name: Market Watch

MRK News

By The Motley Fool
October 31, 2023

Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?

Merck and Daiichi Sankyo just signed a multibillion-dollar drug collaboration. The pair will work to develop three medicines to eventually replace Key

By CNBC Television
October 27, 2023

BMO Capital upgrades Merck to 'outperform'

BMO has upgraded Merck to outperform from market perform.

By Investopedia
October 26, 2023

Merck's Profit Beats Estimates on Sales of Its Cancer, COVID-19 Drugs and HPV Shot

Merck (MRK) posted better-than-expected results on strong sales of its popular Keytruda cancer drug and HPV vaccine Gardasil, as well as a jump in dem

By Seeking Alpha
October 26, 2023

Merck & Co., Inc. (MRK) Q3 2023 Earnings Call Transcript

Merck & Co., Inc. (NYSE:MRK ) Q3 2023 Earnings Conference Call October 26, 2023 9:00 AM ET Company Participants Peter Dannenbaum - Vice President, Inv

By Zacks Investment Research
October 26, 2023

Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales

Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance.

By Zacks Investment Research
October 26, 2023

Merck (MRK) Q3 Earnings and Revenues Beat Estimates

Merck (MRK) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of

By CNBC
October 26, 2023

Merck results beat expectations on strong Keytruda, Gardasil and Covid drug growth

Merck's revenue and earnings beat expectations, and it hiked its sales forecast while lowering its profit outlook.

By Reuters
October 26, 2023

Merck 3rd-quarter profit tops expectations on COVID pill surprise

Merck & Co on Thursday reported higher-than-expected third-quarter sales and profit on surprisingly strong demand for its COVID-19 treatment, primaril

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.